Richard S. Finn, MD, on Advanced Hepatocellular Carcinoma: Expert Perspective
2016 Gastrointestinal Cancers Symposium
Richard S. Finn, MD, of the University of California Los Angeles Medical Center, summarizes a session on treatments for advanced hepatocellular carcinoma (Abstract 192).
Simron Singh, MD
Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).
Dung T. Le, MD
Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, discusses study findings on the safety and activity of nivolumab monotherapy in advanced and metastatic gastric or gastroesophageal junction cancer (Abstract 6).
Dung T. Le, MD
Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, reports findings on this agent, which showed promising activity in patients with previously treated progressive, advanced cancer (Abstract 195).
James L. Abbruzzese, MD
James L. Abbruzzese, MD, of Duke University, discusses the international outlook on patterns of care and their impact on outcomes.
Yoon-Koo Kang, MD, PhD
Yoon-Koo Kang, MD, PhD, of the Asan Medical Center, discusses findings from this multicenter, phase II/III study of ado-trastuzumab emtansine vs a taxane in patients with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (Abstract 5).